OncoMatch/Clinical Trials/NCT06747390
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Is NCT06747390 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Lidocaine 1% Injectable Solution for oropharyngeal squamous cell carcinoma (opscca).
Treatment: Lidocaine 1% Injectable Solution — Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carcinoma (OPSCC). The primary objective of the study is to determine if intratumoral lidocaine injection is safe and causes a major pathologic treatment effect in the primary tumor following surgical resection. The secondary objectives will be to determine if intratumoral lidocaine injection improves locoregional control rates, progression-free survival, metastasis-free survival, and overall survival compared to no injection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Cannot have received: external beam radiation therapy
Prior external beam radiation therapy to the head and neck.
Cannot have received: chemotherapy
Prior chemotherapy for head and neck cancer.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Abramson Cancer Center at University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify